NCT04254549View on ClinicalTrials.gov

Rifaximin in Patients With Diabetic Gastroparesis

PHASE2SuspendedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 14, 2019

Primary Completion Date

April 8, 2025

Study Completion Date

August 31, 2025

Conditions
Crohn DiseaseDiabetic Gastroparesis
Interventions
DRUG

Rifaximin

550 mg by mouth three times daily for 14 days

DRUG

Placebo

By mouth three times daily for 14 days

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04254549 - Rifaximin in Patients With Diabetic Gastroparesis | Biotech Hunter | Biotech Hunter